Skip to main content
padlock icon - secure page this page is secure

Open Access Knockdown of DDX5 Inhibits the Proliferation and Tumorigenesis in Esophageal Cancer

Download Article:
(HTML 44.8 kb)
(PDF 932.9 kb)
DEAD (Asp-Glu-Ala-Asp) box protein 5 (DDX5), a prototypical member of the DEAD/H-box protein family, has been involved in several human malignancies. However, the expression and biological role of DDX5 in esophageal cancer (EC) remain largely unknown. In this study, we examined the role of DDX5 in regulating EC cell proliferation and tumorigenesis and explored its possible molecular mechanism. We found that DDX5 was overexpressed in human EC cell lines. In addition, knockdown of DDX5 significantly inhibited the proliferation of EC cells in vitro and the growth of EC xenografts in vivo. Knockdown of DDX5 also suppressed the migration/invasion and epithelial-to-mesenchymal transition (EMT) phenotype in EC cells. Furthermore, we observed that knockdown of DDX5 inhibited the expression of β-catenin, c-Myc, and cyclin D1 in EC cells. In conclusion, our findings provide the first evidence that siRNA-DDX5 inhibited the proliferation and invasion of EC cells through suppressing the Wnt/β-catenin signaling pathway. Therefore, DDX5 may be a novel potential therapeutic target for the prevention and treatment of EC.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: DEAD (Asp-Glu-Ala-Asp) box protein 5 (DDX5); Esophageal cancer (EC); Invasion; Proliferation

Document Type: Research Article

Affiliations: 1: Department of Thoracic Surgery, The Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 2: Department of Nephrology, The First Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 3: Department of Anesthesia, The Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China

Publication date: July 5, 2017

This article was made available online on December 15, 2016 as a Fast Track article with title: "Knockdown of DDX5 inhibits the proliferation and tumorigenesis in esophageal cancer".

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

    From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more